Physician profile
Manar A Harmouch
NPI 1902242563
$8,034.00
in general payments reported to CMS, 2019-2025
38 companies · $742 in 2025
The $742 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,895 · 2020: $835 · 2021: $781 · 2022: $858 · 2023: $1,497 · 2024: $1,426 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,665.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,287.22 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $713.32 | 2019-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $624.65 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $578.37 | 2019-2025 | Repatha, Otezla, Prolia |
| Pfizer INC. | $571.62 | 2019-2025 | |
| Glaxosmithkline, LLC. | $477.37 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $476.51 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $397.51 | 2019-2023 | Segluromet, Steglujan, Steglatro |
| Abbott Laboratories | $326.65 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.71 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $274.93 | 2022-2025 | Veozah, Myrbetriq |
| Eisai INC. | $238.36 | 2019-2022 | |
| Allergan, INC. | $189.90 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $183.44 | 2023-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $182.54 | 2019-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manar Harmouch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.